Natera Inc
NASDAQ:NTRA

Watchlist Manager
Natera Inc Logo
Natera Inc
NASDAQ:NTRA
Watchlist
Price: 154.58 USD 0.49% Market Closed
Market Cap: 20.9B USD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one NTRA stock under the Base Case scenario is 126.37 USD. Compared to the current market price of 154.58 USD, Natera Inc is Overvalued by 18%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

NTRA Relative Value
Base Case
126.37 USD
Overvaluation 18%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

12.1
P/S
P/S
Price to Sales
12.1
vs History
33
vs Industry
39
Median 3Y
7.3
Median 5Y
9.8
Industry
7.2
Forward
10.6
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-13
Median 5Y
-24.6
Industry
21.4
Forward
-123.3
More Details
151.1
P/OCF
P/OCF
Price to OCF
151.1
vs History
9
vs Industry
1
Median 3Y
-14.9
Median 5Y
-27.2
Industry
20.4
More Details
404.1
P/FCFE
P/FCFE
Price to FCFE
404.1
vs History
4
vs Industry
0
Median 3Y
-14
Median 5Y
-18
Industry
24.5
More Details
17.2
P/B
P/B
Price to Book Value
17.2
vs History
25
vs Industry
5
Median 3Y
10.7
Median 5Y
12.6
Industry
2.4
More Details
11.6
EV/S
EV/S
Enterprise Value to Sales
11.6
vs History
33
vs Industry
34
Median 3Y
6.7
Median 5Y
9.4
Industry
7.4
Forward
10.2
More Details
19.2
EV/GP
EV/GP
Enterprise Value to Gross Profit
19.2
vs History
46
vs Industry
27
Median 3Y
15.1
Median 5Y
18.1
Industry
9.1
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-12.1
Median 5Y
-23.8
Industry
4.1
Forward
-67.8
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-11.8
Median 5Y
-22.6
Industry
3.8
Forward
-61
More Details
144.6
EV/OCF
EV/OCF
Enterprise Value to OCF
144.6
vs History
9
vs Industry
1
Median 3Y
-13.7
Median 5Y
-24.9
Industry
5.1
More Details
333.9
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
333.9
vs History
4
vs Industry
0
Median 3Y
-13.3
Median 5Y
-26.7
Industry
3.3
More Details
29.8
EV/IC
EV/IC
Enterprise Value to IC
29.8
vs History
30
vs Industry
8
Median 3Y
12.7
Median 5Y
20.4
Industry
4.4
More Details

Multiples Across Competitors

NTRA Competitors Multiples
Natera Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Natera Inc
NASDAQ:NTRA
20.5B USD 12.1 -107.7 -102.5 -88.2
FR
Pharnext SCA
OTC:PNEXF
6T USD 36 761 975.8 -174 724.2 -212 170.9 -209 749.7
US
Abbvie Inc
NYSE:ABBV
355.4B USD 6.3 83.9 16.5 24.9
US
Amgen Inc
NASDAQ:AMGN
164.8B USD 4.9 40.3 16.3 28.8
US
Gilead Sciences Inc
NASDAQ:GILD
134.4B USD 4.7 280.1 11 13.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
130.8B USD 11.9 -244.2 26.8 28
US
Epizyme Inc
F:EPE
94.1B EUR 1 916.4 -489 -532.5 -518.3
AU
CSL Ltd
ASX:CSL
122.6B AUD 5.1 28.1 17.3 21.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
69.5B USD 4.9 15.8 10.2 11.3
US
Seagen Inc
F:SGT
39.3B EUR 18.5 -56.6 -60.9 -54.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
36.3B USD 16.2 -130.6 -288.3 -195.9
P/S Multiple
Revenue Growth P/S to Growth
US
Natera Inc
NASDAQ:NTRA
Average P/S: 3 342 179.7
12.1
17%
0.7
FR
Pharnext SCA
OTC:PNEXF
36 761 975.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.3
8%
0.8
US
Amgen Inc
NASDAQ:AMGN
4.9
4%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.7
3%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
11.9
10%
1.2
US
E
Epizyme Inc
F:EPE
1 916.4
N/A N/A
AU
CSL Ltd
ASX:CSL
5.1
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.9
7%
0.7
US
S
Seagen Inc
F:SGT
18.5
30%
0.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.2
28%
0.6
P/E Multiple
Earnings Growth PEG
US
Natera Inc
NASDAQ:NTRA
Average P/E: 89.6
Negative Multiple: -107.7 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -174 724.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
83.9
88%
1
US
Amgen Inc
NASDAQ:AMGN
40.3
44%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
280.1
185%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -244.2 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -489 N/A N/A
AU
CSL Ltd
ASX:CSL
28.1
16%
1.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.8
11%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -56.6 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -130.6 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Natera Inc
NASDAQ:NTRA
Average EV/EBITDA: 16.3
Negative Multiple: -102.5 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -212 170.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.5
13%
1.3
US
Amgen Inc
NASDAQ:AMGN
16.3
17%
1
US
Gilead Sciences Inc
NASDAQ:GILD
11
7%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.8
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -532.5 N/A N/A
AU
CSL Ltd
ASX:CSL
17.3
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.2
14%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.9 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -288.3 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Natera Inc
NASDAQ:NTRA
Average EV/EBIT: 21.4
Negative Multiple: -88.2 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -209 749.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
24.9
28%
0.9
US
Amgen Inc
NASDAQ:AMGN
28.8
31%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
13.8
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28
15%
1.9
US
E
Epizyme Inc
F:EPE
Negative Multiple: -518.3 N/A N/A
AU
CSL Ltd
ASX:CSL
21.7
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.3
17%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.9 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -195.9 N/A N/A

See Also

Summary
NTRA intrinsic value, competitors valuation, and company profile.
DCF Valuation
NTRA stock valuation using Discount Cash Flow valuation method.
Relative Valuation
NTRA stock valuation using valuation multiples.
Wall Street Estimates
NTRA price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
NTRA stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 241,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.